Contact Information: Contact: Richard Oh Taglich Brothers, Inc. 631-757-1500
Taglich Brothers Initiates Coverage on GammaCan International, Inc.
| Source: GammaCan International, Inc.
NEW YORK, NY--(Marketwire - September 21, 2007) - Taglich Brothers, Inc. announces
it initiated coverage of GammaCan International, Inc. (OTCBB : GCAN ).
GammaCan Internatinal, Inc., headquartered in Kiryat Ono,
Israel, has been active in the development of intravenous immunoglobulin
therapy for cancer since 2004. The company's lead product, VitiGam™, is
aimed at treating stage III and IV melanoma with immunotherapy. The
company is also developing an anti-angiogenesis agent as a cancer
treatment.
The complete 18-page report is available at www.taglichbrothers.com.
Taglich Brothers, Inc. is a
full-service broker dealer focused exclusively on microcap companies. The
Company defines the microcap segment of the equity market as companies with
less than $250 million in market capitalization. Taglich Brothers currently
offers institutional and retail brokerage services, investment banking and
comprehensive research coverage to the investment community.
The information and statistical data contained herein have been obtained
from sources, which we believe to be reliable but in no way are warranted
by us as to accuracy or completeness. We do not undertake to advise you as
to changes in figures or our views. This is not a solicitation of any order
to buy or sell. Taglich Brothers, Inc. is fully disclosed with its clearing
firm, Pershing, LLC, is not a market maker and does not sell to or buy from
customers on a principal basis. The above statement is the opinion of
Taglich Brothers, Inc. and is not a guarantee that the target price for the
stock will be met or that predicted business results for the company will
occur. There may be instances when fundamental, technical and quantitative
opinions contained in this report are not in concert. We, our affiliates,
any officer, director or stockholder or any member of their families may
from time to time purchase or sell any of the above-mentioned or related
securities. Analysts and members of the Research Department are prohibited
from buying or selling securities issued by the companies that Taglich
Brothers, Inc. has a research relationship with, except if ownership of
such securities was prior to the start of such relationship, then an
Analyst or member of the Research Department may sell such securities after
obtaining expressed written permission from the Director of Research. As
of the date of this report no Taglich Brothers, Inc. employees had a
position in the stock of the Company mentioned in this report: All
research issued by Taglich Brothers, Inc. is based on public information.
The company paid a $5,000 (USD) engagement fee in August 2007 and will,
commencing upon distribution of our initial report, pay $1,750 (USD) per
month for the creation and dissemination of research reports.
For further information and Taglich Brothers, Inc. ownership data please
refer to each individual report.